Author/Editor		Breznik, Matej
Title		Klaritromicin (Fromilid) v zdravljenju okužb na spodnjih dihalih
Translated title		Clarithromycin (Fromilid) in the treatment of lower respiratory tract infections
Type		članek
Source		Krka Med Farm
Vol. and No.		Letnik 24, št. 35
Publication year		2003
Volume		str. 59-77
Language		slo
Abstract		We analyzed prospective clinical studies of clarithromycin (Fromilid) therapy for community-acquired pneumonia and acute exacerbations of chronic bronchitis, which were carried out between 1998 and 2002 in Slovenia, Russia, the Baltic States (Lithuania, Latvia, Estonia), Bulgaria, the Czech Republic, Poland, Slovakia and Hungary. A total of 466 patients with mild to moderately severe chronic obstructive pulmonary disease were treated with clarithromycin (Fromilid). The treatment was empirical, with an average duration of 8.1 days. Most of the patients (56%) were treated on an outpatient basis. The results of prospective clinical studies have demonstrated that 98% of the patients were either cured or their clinical picture improved significantly. Treatment success depended on the start of treatment with regard to onset of first signs of in fection (p<0.008) and the dose (p<0.05). In Slovenia, a prospective comparative multicentre clinical study was conducted as part of clinical studies of treatrnent of acute exacerbations of chronic bronchitis. The study comprised 78 patients from the University Clinic of Respiratory and Allergic Diseases Golnik and from the Maribor Teaching Hospital Department of Pulmology in Slivniško Pohorje. Treatment with clarithromycin (Fromilid) was more successful than treatment with the amoxicillin plus clavulanic acid combination. 538 patients with mild to moderately severe symptomatic x-ray-confirmed pneumonia were included in the clinical-acquired pneumonia with clarithromycin. 98% of patients were cured or their clinical picture was significantly improved. The treatment was more successful in patients with no underlying diseases (p<0.001). (Abstract trunacted at 2000 characters).
Summary		Analizirali smo prospektivne klinične raziskave zdravljenja zunajbolnišnične pljučnice in akutnih eksacerbacij kronične obstruktivne pljučne bolezni s klaritromicinom (Fromilidom), ki so bile narejene od leta 1998 do leta 2002 v Sloveniji, Rusiji, v pribaltskih državah (Litvi, Latviji, Estoniji), Bolgariji, na Češkem, Poljskem, Slovaškem in Madžarskem. S klaritromicinom (Fromilidom) smo zdravili 466 bolnikov z blago do zmerno kronično obstruktivno pljučno boleznijo. Zdravljenje je bilo izkustveno, trajalo je povprečno 8,1 dneva. Večina bolnikov (56%) se je zdravila ambulantno. Rezultati prospektivnih kliničnih raziskav so pokazali, da je 98% bolnikov ozdravelo ali pa se jim je klinična slika bistveno izboljšala. Uspešnost zdravljenja je bila odvisna od začetka zdravljenja glede na pojav prvih znakov okužbe (p< 0,008) in od odmerka (p < 0,05). V Sloveniji je v okviru kliničnih raziskav zdravljenja akutnih eksacerbacij kronične obstruktivne pljučne bolezni potekala prospektivna primerjalna multicentrična klinična raziskava, v katero je bilo vključenih 78 bolnikov s Kliničnega oddelka za pljučne bolezni in alergijo Bolnišnice Golnik in z Oddelka za pljučne bolezni Splošne bolnišnice Maribor - Učne bolnišnice na Slivniškem Pohorju. Zdravljenje s klaritromicinorn (Fromilidom) je bilo uspešnejše od zdravljenja s kombinacijo arnoksicilina in klavulanske kisline. V prospektivne klinične raziskave zdravljenja zunajbolnišničlne pljučnice s klaritromicinom je bilo vključenih 538 bolnikov z blago do zmerno hudo simptomatsko pljučnico, potrjeno z rentgensko sliko. 98% bolnikov je ozdravelo ali se jim je klinična slika bistveno izboljšala. Zdravljenje je bilo uspešnejše pri bolnikih, ki niso imeli drugih bolezni (p<0,001). (Izvleček prekinjen pri 2000 znakih).
Descriptors		RESPIRATORY TRACT INFECTIONS CLARITHROMYCIN BRONCHITIS PNEUMONIA LUNG DISEASES, OBSTRUCTIVE COMMUNITY-ACQUIRED INFECTIONS DYSPNEA COUGH SPUTUM TREATMENT OUTCOME